CeGaT Is One of the First Companies Worldwide to Receive the Most Powerful Sequencing Platform NovaSeq™ X Plus

(PresseBox) (Tübingen, 14.03.2023) 

CeGaT, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, is now using the latest and most powerful sequencing system from Illumina. With the NovaSeq™ X Plus, CeGaT can carry out research projects previously considered unfeasible due to their enormous data volume.

Since mid-March, CeGaT has been one of the first companies worldwide to own the brand new NovaSeq™ X Plus, which was announced by Illumina just last fall. Thanks to innovative chemistry and technology, the high-performance sequencer enables an unmatched level of throughput and accuracy: In one run with two flow cells, up to 16 terabases are generated in the shortest possible time. As a result, tens of thousands of genomes can be sequenced yearly. The acquisition of this platform allows CeGaT to meet the increasing demand for molecular genetic analyses and thus make this revolutionary technology available to its customers.

Innovative and sustainable

Dr. Dirk Biskup, managing director, and co-founder of CeGaT, explains, "We look forward to realizing even the most extensive projects in our usual outstanding quality with the NovaSeq™ X Plus. Researchers will be able to complete their studies faster and more efficiently than ever before. The fact that the NovaSeq™ X Plus is also an innovation in ecological terms and saves considerably on resources during operation fits perfectly with our guiding principle of sustainability in all areas of the company."

"We are delighted that CeGaT has taken delivery of one of the first NovaSeq™ X Plus instruments in Europe as it continues to invest to meet the increasing demand for sequencing and genetic analyses," said Bas Verhoef, Head of Region, Europe, Illumina. With its new chemistry, the NovaSeq X series allows our customers to maximize their productivity and minimize turnaround time, that will further our understanding of genetic diseases to improve human health.”

The NovaSeq™ X Plus will be used for a wide range of genomics applications. CeGaT's business unit, "Research and Pharma Solutions", offers customers from science, pharma, and industry a wide range of sequencing services that are also used in clinical studies under the highest regulatory requirements.

Continuous investment in state-of-the-art technologies

CeGaT continually invests in acquiring the latest technology. The Tübingen-based company recently became the first provider in Germany to acquire PacBio's Sequel IIe system. The Single Molecule Real-Time (SMRT) technology behind it enables Hi-Fi reads with exceptional accuracy and length. With the acquisition of the NovaSeq™ X Plus, CeGaT underpins its pioneering role in the field of sequencing.